Skip to main content
. 2022 Oct 18;17(10):e0263861. doi: 10.1371/journal.pone.0263861

Fig 7. Salivary IgA specific to SARS-CoV-2 RBD in N = 40 individuals prior first (V1), three weeks after first (V2) and to weeks after second vaccination (P1) in comparison with COVID-19 patients (N = 31).

Fig 7

The dotted line indicates the 95% interquartile range for vaccinees.